We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.
Kristen Harrison, MPH
Advertisement
Articles by Kristen Harrison, MPH
With new drugs in the pipeline and the impact of updated FDA drug safety policies on colchicine, gout may no longer be inexpensive to treat.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Functional Cure of Hepatitis B Infections Among Patients Coinfected With HIV
2
White Bagging, Brown Bagging, and the Pharmacist Caught in the Middle
3
New Climate Model May Help Predict Influenza Outbreaks Worldwide
4
Connecting Care in a Changing Health System
5